Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Study results from L. Annemans and colleagues in the area of cancer vaccines published
June 24th, 2009
According to recent research from Lyon, France, "The introduction of a quadrivalent human papillomavirus (HPV; types 6, 11, 16, 18) vaccine is expected to significantly reduce the burden of cervical cancer, cervical intraepithelial neoplasia (CIN), genital warts and other HPV-related diseases. To determine the cost effectiveness of providing a quadrivalent (6,11,16,18) HPV vaccine programme in adolescent females aged 12 years in addition to the existing cervical cancer screening programme in Belgium." "A Markov state-transition model was developed for the Belgian context. in order to evaluate the long-term impact of vaccinating a cohort of girls aged 12 years alongside...
Source: Vaccine Weekly (2009-06-24)
|
